Skip to main content

Table 1 Patient and clinical characteristics (N = 169)

From: Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer

CharacteristicsBRCA wild-type (N = 122)BRCA mutation (N = 47)P
Age, median (range), years57 (32–77)56 (27–76)0.610
CA-125 level, median (range), U/mL1958.7 (94.2.0–21,994.8)1711.3 (75.0–23,919.0)0.759
FIGO stage, n (%)
 III56 (45.9%)23 (48.9%)0.734
 IV66 (54.4%)24 (51.1%) 
Grading
 13 (2.5%)0 (0%)0.489
 211 (9.0%)2 (4.5%) 
 3102 (83.6%)42 (89.4%) 
Not available6 (4.9%)3 (6.4%) 
Tumor burden assessed by diagnostic laparoscopy*
 PIV 827 (22.1%)3 (6.4%)0.097
 PIV 1025 (20.5%)14 (29.8%) 
 PIV 1210 (8.2%)4 (8.5%) 
 PIV 145 (4.1%)1 (2.1%) 
 Not available55 (45.1%)25 (53.2%) 
CRS, n (%)
 1–279 (64.8%)31 (66.0%)0.516
 343 (35.2%)16 (34.0%) 
Residual disease, n (%)
 No62 (50.8%)18 (38.3%)0.344
 Any residual58 (47.5%)28 (59.6%) 
 Not available2 (1.6%)1 (2.1%) 
Radical surgery, n (%)   
 None59 (48.4%)19 (40.4%)0.354
 Any radical surgery63 (51.6%)28 (59.6%) 
Surgical complexity score groups
 1–2 (Low/intermediate)102 (83.6%)37 (78.7%)0.457
 8 (High)20 (16.4%)10 (21.3%) 
Chemotherapy regimen, n (%)
 Paclitaxel + carboplatin91 (74.6%)34 (72.3%)0.576
 Docetaxel + carboplatin8 (6.6%)6 (12.8%) 
 Weekly paclitaxel + carboplatin15 (12.3%)5 (10.6%) 
 Paclitaxel + carboplatin + bevacizumab8 (6.6%)2 (4.3%) 
  1. * According to Fagotti et al. [15]
  2. Radical surgery includes any of following: bowel surgery, cholecystectomy, diaphragm peritonectomy/resection, distal pancreatectomy video-assisted thoracoscopic surgery, splenectomy, liver resection, supraclavicular fossa resection, ureter resection, and others
  3. According to Aletti et al. [19]
  4. CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; HGSC, high-grade serous carcinoma; PIV, predictive index value; CRS, chemotherapy response score